Mutated IDH in AML

A Simple Concept for a Complex Disease

Sign up for Updates

Receive periodic updates and more information about IDH mutations and AML. *Required

dot

dot

dot

dot

dot

dot

dot

Approximately 20% of patients with AML have an IDH mutation^1,2
- Mutated IDH leads to a block on myeloid differentiation and an accumulation of myeloblasts: the hallmark of AML^1,3
Greater than 99% of patients with AML have at least 1 gene mutation^4*
- Molecular profiling is important to identify gene mutations associated with AML⁵
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) suggest molecular profiling in patients with relapsed/refractory AML to assist with selection of appropriate clinical trials⁶
- Your pathologist can help you determine the best method for molecular profiling in AML
- Clinical trials are available for patients with newly diagnosed or relapsed/refractory AML who harbor IDH mutations⁷

Based on a recent analysis of 200 patients with de novo AML.
AML, acute myeloid leukemia; IDH, isocitrate dehydrogenase.

References: 1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152. 2. McKenney AS, Levine RL. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest.2013;123(9):3672-3677. 3. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567. 4. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2054. 5. Patel K, Ravandi F, Ma D, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011;135(1):35-45. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2016. © National Comprehensive Cancer Network, Inc 2016. All rights reserved. Accessed November 11, 2016. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 7. ClinicalTrials.gov [database online]. Accessed August 3, 2016.